

NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.

De Groot LJ, Chrousos G, Dungan K, et al., editors. Endotext [Internet]. South Dartmouth (MA): MDText.com, Inc.; 2000-.

## Management of Diabetes and Hyperglycemia in Hospitalized Patients

Leonor Corsino, MD, MHS, FACE

Duke University Medical Center, Durham, North Carolina, U.S.A.

Ketan Dhatariya

Norfolk and Norwich University Hospitals, Colney Lane, Norwich.

Guillermo Umpierrez

Emory University. Atlanta, Georgia, U.S.A.

Last Update: October 4, 2014.

### INTRODUCTION

Diabetes is a prevalent metabolic disorder that affects more than 340 million people globally<sup>(1)</sup>. In the United States, data from the National Diabetes Statistics recently reported that in 2012, a total of 29.1 million Americans, or 9.3% of the population, had diabetes<sup>(2)</sup>. The percentage of the population with diagnosed diabetes is expected to rise, with one study projecting that as many as one in three U.S. adults will have diabetes by 2050<sup>(3)</sup>. Patients with diabetes have a 3-fold greater chance of hospitalization compared to those without diabetes<sup>(4,5)</sup>, and it is estimated that more than 20% of all adults discharged have diabetes, with 30% of them requiring 2 or more hospitalizations in any given year<sup>(4-6)</sup>. In 2012 in the U.S., there were over 7.7 million hospital stays for patients with diabetes (i.e., diabetes as either a principal diagnosis for hospitalization or as a secondary diagnosis, coexisting condition). Diabetes remains the 7th leading cause of death in the United States in 2010, with 69,071 death certificates listing it as the underlying cause of death, and a total of 234,051 death certificates listing diabetes as an underlying or contributing cause of death<sup>(2)</sup>. The care of patients with diabetes imposes a substantial burden on the economy<sup>(7)</sup>. The total estimated cost of diagnosed diabetes in the United States in 2012 was \$245 billion; including \$176 billion in direct medical costs and \$69 billion in reduced productivity. The largest components of medical expenditures are hospital inpatient care (43% of the total medical cost)<sup>(7)</sup>.

Hyperglycemia and diabetes in the hospital setting affect 38% to 46% of non-critically ill hospitalized patients<sup>(1,2)</sup>. Extensive data from observational and randomized controlled trials indicate that inpatient hyperglycemia, in patients with or without a prior diagnosis of diabetes, is associated with an increased risk of complications and mortality, a longer hospital stay, a higher admission rate to the intensive care unit (ICU), and a higher need for transitional or nursing home care after hospital discharge<sup>(1,3,4)</sup>. It is also well established that improvement in glucose control with goal-directed insulin regimens reduces hospital complications and mortality in critically ill, as well as in general medicine and surgery patients<sup>(6-11)</sup>.

Recent studies and meta-analyses have shown that intensive insulin therapy is associated with increased risk of hypoglycemia<sup>(12-15)</sup>, which has been independently associated with increased morbidity and mortality in hospitalized patients<sup>(15)</sup>. Thus, while insulin therapy is recommended for the management of hyperglycemia in hospitalized patients<sup>(11,16)</sup>, the concern about hypoglycemia has led to revised glucose target recommendations from professional organizations<sup>(8,9)</sup>, and search of alternative treatment options<sup>(17,18)</sup>.


This chapter reviews the pathophysiology of hyperglycemia during illness, the mechanisms for increased complications and mortality due to hyperglycemia and hypoglycemia, and reviews the evidence on the different therapies available for the management of inpatient diabetes and hyperglycemia in the critical care and in the general medicine and surgical settings.

### PREVALENCE OF DIABETES AND HYPERGLYCEMIA IN THE HOSPITALIZED PATIENT.

Observational studies have reported a prevalence of hyperglycemia and diabetes ranging from 32% to 38% in community hospitals (<sup>6,10</sup>) and in 70-80% of diabetic patients with critical illnesses (<sup>11</sup>) and cardiac surgery (<sup>19,20</sup>). A recent report using point-of-care bedside glucose tests data in 3,484,795 patients (653,359 ICU and 2,831,436 non-ICU) from 575 hospitals in the United States reported a prevalence of hyperglycemia, defined as a glucose level >180 mg/dl, of 32.2% in ICU patients and in 32.0% of non-ICU patients (<sup>21</sup>). These numbers included patients with newly identified or stress hyperglycemia as well as diabetes. The American Diabetes Association (ADA) and American Association of Clinical Endocrinologists (AACE) consensus on inpatient hyperglycemia defined stress hyperglycemia or hospital-related hyperglycemia as any blood glucose concentration > 7.8 mmol/l (140 mg/dl). Although stress hyperglycemia typically resolves as the acute illness or surgical stress abates, about 60% of such patients had confirmed diabetes at 1 year (<sup>22</sup>). Measurement of an HbA1c is indicated in patients with hyperglycemia without a history of diabetes to differentiate between stress hyperglycemia and previously undiagnosed diabetes (<sup>23,24</sup>). The Endocrine Society recommendations indicate that hospitalized patients with elevated blood glucose an HbA1C of 6.5% (48 mmol/mol) or higher can be identified as having diabetes (<sup>12</sup>).

### **PATHOPHYSIOLOGY OF HYPERGLYCEMIA DURING ILLNESS**

In normal subjects during fasting state, plasma glucose is maintained between 3.9 – 5.6 mmol/l (70-100 mg/dl) by a finely regulated balance between hepatic glucose production and glucose utilization in peripheral tissues. Maintenance of normal glucose level is essential for central nervous system function as the brain can neither synthesize nor store glucose (<sup>13</sup>). Systemic glucose balance is maintained by dynamic, minute-to-minute regulation of endogenous glucose production and of glucose utilization by peripheral tissues (<sup>14-16</sup>). Glucose production is accomplished by gluconeogenesis or glycogenolysis primarily in the liver and in a lesser degree by the kidneys (<sup>16</sup>). Gluconeogenesis results from conversion of non-carbohydrate precursors such as lactate, alanine, and glycerol to glucose in the liver. Excess glucose is polymerized to glycogen, which is mainly stored in the liver and muscle. Hyperglycemia develops as a result of three processes: increased gluconeogenesis, accelerated glycogenolysis, and impaired glucose utilization by peripheral tissues (Figure 1) (<sup>17</sup>).



From the quantitative standpoint, increased hepatic glucose production represents the major pathogenic disturbance. Increased hepatic glucose production results from the high availability of gluconeogenic precursors including the amino acids alanine and glutamine, as a result of accelerated proteolysis and decreased protein synthesis; lactate as a result of increased muscle glycogenolysis; and glycerol as a result of increased lipolysis; and from the increased activity of gluconeogenic enzymes (phosphoenol pyruvate carboxykinase, fructose-1,6-bisphosphatase, and pyruvate carboxylase) (16,18,25).

Glucose metabolism is maintained by an interaction of glucoregulatory hormones - insulin and counterregulatory hormones (glucagon, cortisol, growth hormone and catecholamines). Insulin controls hepatic glucose production by suppressing hepatic gluconeogenesis and glycogenolysis. In insulin-sensitive tissues such as muscle, insulin promotes

protein anabolism, glucose uptake and glycogen synthesis, and inhibits glycogenolysis and protein breakdown<sup>(13,26)</sup>. In addition, insulin is a powerful inhibitor of lipolysis, free fatty acid oxidation, and ketogenesis<sup>(13,26)</sup>. Counterregulatory hormones (glucagon, cortisol, growth hormone and catecholamines) also play an important role in the regulation of glucose production and utilization. Glucagon is the most important glycogenolytic hormone, and therefore regulates hepatic glucose production during the normal state and in every state of hyperglycemia<sup>(16)</sup>. During stress, excess concentration of counterregulatory hormones result in altered carbohydrate metabolism by inducing insulin resistance, increasing hepatic glucose production, and reducing peripheral glucose utilization. In addition, high epinephrine levels stimulate glucagon secretion and inhibit insulin release by pancreatic  $\beta$ -cells<sup>(27)</sup>.

The development of hyperglycemia results in an inflammatory state characterized by an elevation of pro-inflammatory cytokines and increased oxidative stress markers<sup>(28,29)</sup>. Circulating levels of tumor necrosis factor- $\alpha$ , interleukin [IL]-6, IL-1 $\beta$ , and IL-8, C-reactive protein are significantly increased two- to fourfold on admission in patients with severe hyperglycemia compared with control subjects, and levels returned to normal levels after insulin treatment and resolution of hyperglycemic crises<sup>(28)</sup>. TNF- $\alpha$  leads to insulin resistance by interaction at the level of the insulin receptor and through altered regulation of the insulin-signaling pathway. Increasing evidence indicates that during acute stressful states, increased circulating inflammatory cytokines including tumor necrosis factor- $\alpha$  (TNF- $\alpha$ ), interleukin (IL)-6, and IL-1 can increase insulin resistance by interfering with insulin signaling<sup>(28,30-32)</sup>. In addition, TNF- $\alpha$ , by preventing insulin-mediated activation of phosphatidylinositol 3-kinase, reduces insulin-stimulated glucose uptake in peripheral tissues<sup>(33,34)</sup>.

## CONSEQUENCES OF HYPERGLYCEMIA IN THE HOSPITALIZED PATIENTS

A large body of literature including observational and prospective randomized clinical trials, in patients with and without diabetes, as well as in critically ill and non-critically ill patients has shown a strong association between hyperglycemia and poor clinical outcomes, such as mortality, infections and hospital complications<sup>(6,35-37)</sup>. This association correlates with severity of hyperglycemia on admission as well as during the hospital stay<sup>(35,38,39)</sup>. Of interest, increasing evidence indicates an increased risk of complications and mortality in patients without a history of diabetes (stress induced) compared to patients with known diagnosis of diabetes<sup>(6,35,40)</sup>. It is not clear if stress hyperglycemia is the direct cause of poor outcomes or it is a general marker of severity of illness.

The mechanisms implicated on the detrimental effects of hyperglycemia during acute illnesses are not completely understood. Current evidence indicates that severe hyperglycemia results in impaired neutrophil granulocyte function, high circulating free fatty acids, and overproduction of pro-inflammatory cytokines and reactive oxygen species (ROS) that can result in direct cellular damage, and vascular and immune dysfunction<sup>(41)</sup>.

The majority of evidence linking hyperglycemia and poor outcomes comes from studies in the ICU. Falciglia et al in a retrospective study of over 250,000 veterans admitted to various ICUs reported that hyperglycemia is an independent risk factor for mortality and complications<sup>(35)</sup>. In a nonrandomized, prospective study, Furnary followed 3,554 patients with diabetes that underwent coronary artery bypass graft. Patients treated with subcutaneous insulin (SCI) who had an average blood glucose of 11.9 mmol/l (214 mg/dl) and patients treated with continuous insulin infusion (CII) with an average blood glucose of 9.8 mmol/l (177 mg/dl) had significantly more deep sternal wound infections<sup>(39)</sup> and a 50% higher risk-adjusted mortality<sup>(36)</sup>. In a different ICU study, patients with blood glucose levels >11.1 mmol/l (>200 mg/dl) were shown to have higher mortality compared to those with blood glucose levels <11.1 mmol/l (<200 mg/dl) (5.0% vs. 1.8%,  $p < 0.001$ )<sup>(39)</sup>.

The association of hyperglycemia and poor outcomes also applies to non-ICU patients admitted to general medicine and surgery services. In such patients, hyperglycemia is associated with poor hospital outcomes including prolonged hospital stay, infections, disability after hospital discharge and death<sup>(6,42)</sup>. In a retrospective study of 1,886 patients admitted to a community hospital, mortality in the general floors was significantly higher in patients with newly (stress) diagnosed hyperglycemia and with known diabetes compared to subjects with normal glucose values (10% vs.

1.7% vs. 0.8%, respectively;  $p < 0.01$ )<sup>(6)</sup>. In a prospective cohort multicenter study of 2,471 patients with community-acquired pneumonia, those with admission glucose levels of  $> 11$  mmol/l (198 mg/dl) had a greater risk of mortality and complications than those with glucose  $< 11$  mmol/l (198 mg/dl). The risk of complications increased 3% for each 1 mmol/l (18 mg/dl) increase in admission glucose<sup>(43)</sup>. In a retrospective study of 348 patients with chronic obstructive pulmonary disease and respiratory tract infection, the relative risk of death was 2.1 in those with a blood glucose of 7-8.9 mmol/l (126-160 mg/dl), and 3.4 for those with a blood glucose of  $>9.0$  mmol/l ( $>162$  mg/dl) compared to patients with a blood glucose of 6.0 mmol/l (108 mg/dl)<sup>(44)</sup>.

General surgery patients with hyperglycemia during the perioperative period are also at increased risk for adverse outcomes. In a case-control study, elevated preoperative glucose levels increased the risk of postoperative mortality in patients undergoing elective non-cardiac non-vascular surgery<sup>(45)</sup>. Patients with glucose levels of 5.6-11.1 mmol/l (110-200 mg/dl) and those with glucose levels of  $>11.1$  mmol/l ( $>200$  mg/dl) had, respectively, 1.7-fold and 2.1-fold increased mortality compared to those with glucose levels  $< 5.6$  mmol/l ( $<110$  mg/dl)<sup>(46)</sup>. In another study, patients with glucose levels  $>12.2$  mmol/l ( $> 220$  mg/dl) on the first postoperative day had a rate of infection 2.7 times higher than those who had serum glucose levels  $<12.2$  mmol/l<sup>(45)</sup>. A more recent study<sup>(47)</sup> showed an increase of postoperative infection rate by 30% for every 2.2 mmol/l (40 mg/dl) rise in postoperative glucose level above 50 mmol/l (110 mg/dl).

## GLYCEMIC TARGETS IN ICU AND NON-ICU SETTINGS

The American Diabetes Association (ADA) and American Association of Clinical Endocrinologist (AACE) task force on inpatient glycemic control recommended a change in glycemic targets in the ICU setting<sup>(9)</sup> Table 1. These guidelines suggest targeting a blood glucose (BG) level between 7.8 and 10.0 mmol/l (140 and 180 mg/dl) for the majority of ICU patients and a lower glucose targets between 6.1 and 7.8 mmol/l (110 and 140 mg/dl) in selected ICU patients (i.e. centers with extensive experience and appropriate nursing support, cardiac surgical patients, patients with stable glycemic control without hypoglycemia). Glucose targets  $>10$  mmol/l ( $>180$  mg/dl) or  $<6.1$  mmol/l ( $< 110$  mg/dl) are not recommended in ICU patients.

Recent guidelines from the Society of Critical Care Medicine (SCCM) for the management of hyperglycemia in critically ill (ICU) patients<sup>(48)</sup> recommended that a blood glucose  $\geq 150$  mg/dl (8.3 mmol/l) should trigger interventions to maintain blood glucose below that level and absolutely  $<180$  mg/dl (10 mmol/l). They suggest that the insulin regimen and monitoring system be designed to avoid and detect hypoglycemia (blood glucose  $< 3.9$  mmol/l [70 mg/dl]) and to minimize glycemic variability. The technology to allow this to occur is in development and may be ready for routine clinical use relatively soon<sup>(49,50)</sup>. In the non-ICU setting, the Endocrine Society and the ADA/AACE Practice Guidelines<sup>(9,12,51)</sup> recommended a pre-meal glucose of  $<140$  mg/dl (7.8 mmol/l) and a random BG of  $<10.0$  mmol/l (180 mg/dl) for the majority of non-critically ill patients treated with insulin. To avoid hypoglycemia  $<3.9$  mmol/l (70 mg/dl), the total basal and prandial insulin dose should be reduced if glucose levels fall between 3.9 mmol/L and 5.6 mmol/l (70-100 mg/dl). In contrast, higher glucose ranges (11.1 mmol/l or 200 mg/dl) may be acceptable in terminally ill patients or in patients with severe comorbidities as a way of avoiding symptomatic hyperglycemia<sup>(12)</sup>.

**Table 1 Major Guidelines for Treatment of hyperglycemia in a hospital setting.**

	ICU	Non-ICU
ADA/AACE <sup>9,51</sup>	Initiate insulin therapy for persistent hyperglycemia (glucose $>180$ mg/dl [10 mmol/l]) Treatment goal: For most patients, target a glucose level between 140-180 mg/dl. More stringent goals (110-140 mg/dl) may be appropriate for	No specific guidelines If treated with insulin, pre-meal glucose targets should generally be $<140$ mg/dL, with random glucose levels $<180$ mg/dL More stringent targets may be appropriate for patients with previously tight glycemic control Less stringent targets may be appropriate in patients with severe

	selected patients, if achievable without significant risk for hypoglycemia	comorbidities
<b>ACP<sup>8</sup></b>	Recommends against intensive insulin therapy in patients with or without diabetes in surgical/medical ICUs Treatment goal: target glucose between 140-200 mg/dl, in patients with or without diabetes, in surgical/medical ICUs	
<b>Critical Care Society<sup>48</sup></b>	BG >150 mg/dl should trigger insulin therapy Treatment goal: maintain glucose <150 mg/dl for most adult patients in ICU Maintain glucose levels <180 mg/dl while avoiding hypoglycemia	—
<b>Endocrine Society<sup>12</sup></b>	—	Pre-meal glucose target <140 mg/dl and random blood glucose <180 mg/dl A lower target range may be appropriate in patients able to achieve and maintain glycemic control without hypoglycemia Glucose <180-200 mg/dl is appropriate in patients with terminal illness and/or with limited life expectancy or at high risk for hypoglycemia Adjust antidiabetic therapy when glucose falls <100 mg/dl to avoid hypoglycemia
<b>Society of Thoracic Surgeons<sup>117</sup></b> (Guidelines specific to adult cardiac surgery)	Continuous insulin infusion preferred over SC or intermittent intravenous boluses Treatment goal: Recommend glucose <180 mg/dL during surgery (≤110 mg/dL in fasting and pre-meal states)	
<b>Joint British Diabetes Society<sup>52</sup></b>		Target blood glucose levels in most people of between 6 and 10 mmol/L (108-180 mg/dl) with an acceptable range of between 4 and 12mmol/L (72 – 216mg/dl)

AACE/ADA, American Association of Endocrinologists and American Diabetes Association joint guidelines; ACP, American College of Physicians; ADA, American Diabetes Association; ICU, intensive care unit; IV

Guidelines from the Joint British Diabetes Society's Inpatient Care Group in the UK (<sup>52</sup>) published over the last few years, aim for target blood glucose levels in most people between 6 and 10 mmol/l (108-180 mg/dl) with an acceptable range between 4 and 12mmol/L (72 – 216mg/dl). [Table 1](#) summarize the currently available guidelines for the management of hyperglycemia in the hospital setting.

## EVIDENCE FOR CONTROLLING HYPERGLYCEMIA IN ICU AND NON-ICU SETTINGS

The Leuven SICU study set the stage for intensive glycemic control in the critical care setting a decade ago. This study randomized 1,548 patients admitted to the surgical ICU (63% cardiac cases, 13% with diabetes, most patients received early parenteral nutrition). Patients were randomized to either conventional therapy with a target glucose between 10 and 11.1 mmol/l (180-200 mg/dl) or intensive therapy to a target glucose between 4.4 and 6.1 mmol/l (80-110 mg/dl).

Patients in the conventional arm had a mean daily glucose average of 8.5 mmol/l (153 mg/dl) and patients in the intensive arm had an average glucose of 5.7 mmol/l (103 mg/dl). Those in the intensive group had significantly less bacteremia, less antibiotic requirements, lower length of ventilator dependency, lower number of ICU days and an overall 34% reduction in mortality<sup>(20)</sup>. Following a similar study design, the same group of investigators randomized medical ICU patients (18% with diabetes) and reported that intensive insulin therapy (mean daily glucose of 6.2 mmol/l (111 mg/dl)) resulted in less ICU and total hospital complications in patients with 3 days of insulin treatment<sup>(53)</sup>. These two studies together, based on the positive outcomes on morbidity and mortality, suggested a glycemic target in the ICU of 4.4-6.1 mmol/l (80-110mg/dl)<sup>(9,51)</sup>.

A large number of well-designed randomized controlled trials and meta-analyses have, however, shown that such a low glucose target has been difficult to achieve without increasing the risk for severe hypoglycemia<sup>(54-57)</sup>. In addition, these studies failed to show improvement in clinical outcomes and have even shown increased mortality risk with intensive glycemic control Table 2<sup>(54-58)</sup>. The Glucontrol trial, a seven-country multicenter trial, randomized patients in medical and surgical ICUs to tight glycemic control (4.4-6.1 mmol/l; 80-110 mg/dl) versus conventional glycemic control (7.8-10 mmol/l; 140-180 mg/dl). The study did not find a difference in mortality between the two groups<sup>(59)</sup>. The Efficacy of Volume Substitution and Insulin Therapy in Sepsis (VISEP) study was another trial that attempted to reproduce the data from the Leuven trial. The study was a multicenter study in Germany that randomized patients with sepsis to receive intensive insulin therapy to maintain glucose levels 10-11.1 mmol/l (180-200 mg/dl) versus the intensive arm of 4.4-6.1 mmol/l (80 -110 mg/dl)<sup>(54)</sup>. The investigators evaluated differences between the groups in 28- and 90-day mortality, sepsis-related organ failure, ICU stay and frequency of hypoglycemia (BG < 2.2 mmol/l; < 40mg/dl). The trial was stopped prematurely after reaching only ~2/3 of the projected enrollment due to an interim analysis that showed no difference in 28- or 90-day mortality between patients treated in the conventional arm versus those in the intensive arm (21.6% vs. 21.9%; 29.5 vs. 32.8%, respectively), but those in the intensive arm experienced a significantly greater amount of severe hypoglycemia (12.1 vs. 2.1%).

**Table 2 Clinical Trials of Intensive Glycemic Control in ICU Populations**

Study	Setting	Population	Clinical Outcome
Malmberg <sup>88</sup> , 1994	CCU	Mixed	28% decrease mortality After 1 year <sup>88</sup>
Furnary <sup>39</sup> , 1999	CCU	DM undergoing CABG	65% decrease in deep sterna wound infection rate <sup>39</sup>
Van den Berghe <sup>20</sup> , 2001	Surgical ICU	Mixed, with CABG	34% decrease mortality <sup>20*</sup>
Furnary <sup>36</sup> , 2003	CCU	DM undergoing CABG	50% decrease in adjusted mortality rate <sup>36</sup>
Krinsley <sup>38</sup> , 2003	Med-surgical ICU	Mixed	27% decrease in mortality <sup>38</sup>
Lazar <sup>118</sup> , 2004	OR and ICU	DM with CABG	60% decrease of post-operative atrial fibrillation <sup>118</sup>
Van den Berghe <sup>53</sup> , 2006	Medical ICU	Mixed	18% decrease mortality <sup>53*</sup>
Gandhi <sup>119</sup> , 2007	Operating Room	Mixed, cardiac surgery	No difference in mortality; increase in stroke rate in IT arm <sup>119</sup>
VISEP <sup>54</sup> , 2008	Medical ICU	Mixed w/ sepsis	No difference in 28-day or 90-day mortality, end-organ failure, LOS <sup>54*</sup>
De La Rosa <sup>55</sup> , 2008	Med-surgical ICU	Mixed	No difference in 28-day mortality or infection rate <sup>55</sup>

Glucontrol <sup>59</sup> , 2009	Med-surgical ICU	Mixed	No difference in 28-day mortality <sup>59*</sup>
NICE-SUGAR <sup>58,120</sup> , 2009/2012	Med-surgical ICU	Mixed	No difference in 90-day mortality <sup>58,120</sup>
Boston Children's (SPECS) <sup>121</sup> , 2012	Cardiac ICU	Cardiac surgery, non diabetics	No difference in 30-day mortality, length of stay in the cardiac ICU, length of hospital, duration of mechanical ventilation and vasoactive support, or measures of organ failure <sup>121</sup> .
ChiP <sup>122</sup> , 2014	Pediatric-ICU	Critical illness/injury /major surgery, non diabetics.	No difference in 30-day mortality, increase hypoglycemia in the intensive treated group <sup>122</sup> .
CGAO-REA <sup>97,123</sup> , 2014	Medical ICU	Mixed	No difference in 90-day mortality, increase hypoglycemia in the intensive treated group <sup>97,123</sup> .
Okabayashi <sup>124</sup> , 2014	Surgical ICU	Mixed	Decrease surgical site infection in the intensive treated group <sup>124</sup> .

IT=intensive therapy; CT=conventional therapy

\*Study underpowered due to premature discontinuation

Mixed=non diabetics and diabetics

The NICE-SUGAR trial (<sup>56</sup>) randomized over 6000 subjects to receive either conventional glycaemic control (<10 mmol/l; <180 mg/dl) or intensive glycaemic control (4.5-6 mmol/l; 81-108 mg/dl) and also reported no difference in-hospital mortality, but found increased mortality at 90 days of follow-up (24.9% vs. 27.5%, p=0.02). In a subsequent analysis of the trial, the NICE SUGAR investigators reported a higher frequency of hypoglycemia in the intensive arm (6.8% vs. 0.5%) and those with hypoglycemia had ~2-fold increase in mortality compared to patients without hypoglycemia (<sup>60</sup>).

Today no large studies have been conducted to determine if improved control in non-ICU patients may result in reduced morbidity and mortality in general medicine and surgery patients. A recent randomized controlled trial and a meta-analysis have shown that improved glucose control may reduce hospital complications in general surgery patients (<sup>37</sup>). Improving glucose control with a basal bolus regimen resulted in significantly reduction in the frequency of composite complications including postoperative wound infection, pneumonia, bacteremia, and acute renal and respiratory failure (<sup>61</sup>).

## HYPOGLYCEMIA

Hypoglycemia is the commonest side effect of treatment of all types of diabetes in the hospital setting. It presents a major barrier to satisfactory long-term glycaemic control. Hypoglycemia results from an imbalance between glucose supply, glucose utilization and current insulin levels. Hypoglycemia is defined as a lower than normal level of blood glucose. For the purposes of hospital inpatients, hypoglycemia is defined as any glucose level <3.9 mmol/l (70 mg/dl). (<sup>62,63</sup>) Severe hypoglycemia has been defined by many as <2.2 mmol/l (40 mg/dl) (<sup>63</sup>). The incidence of severe hypoglycemia among the different trials ranged between 5% and 28% depending on the intensity of glycaemic control in the ICU (<sup>64</sup>) while rates from trials using subcutaneous insulin in non-critically ill patients range from less than 1% to 33% (<sup>65,66</sup>). In 2012, the UK National Diabetes Inpatient Audit (NaDIA) data showed 22.4 % of patients with diabetes experienced one or more hypoglycemic episodes with a blood glucose less than 4.0 mmol/l (72mg/dl), with 10.5% experiencing one or more hypoglycemic episodes less than 3.0mmol/L (54mg/dl)(13). The NaDIA data from 2012 showed that patients with type 1 diabetes had the highest prevalence with 40.4% experiencing a hypoglycemic

episode between 3-4 mmol/l and 28.8% experiencing a hypoglycemic episode <3mmol/L. The same data showed that the highest proportion of episodes took place overnight (34.3%) between 9pm and 9am when snack availability was likely to have been lowest<sup>(67)</sup>.

Further, recent data published from NaDia using data from 41 Trusts showed 12 serious adverse events including three deaths; two cases of permanent cerebral damage; two successfully resuscitated cardiac arrests; three seizures; and two undefined events. Insulin therapy was implicated in 10 events<sup>(68)</sup>. The key predictors of hypoglycemic events in hospitalized patients include older age, greater illness severity, diabetes, and the use of oral glucose lowering medications and insulin<sup>(69,70)</sup>. In-hospital processes of care that contribute to risk for hypoglycemia include unexpected changes in nutritional intake that are not accompanied by associated changes in the glycemic management regimen (e.g., cessation of nutrition for procedures, adjustment in the amount of nutritional support), interruption of the established routine for glucose monitoring, deviations from the established glucose control protocols, and failure to adjust therapy when glucose is trending down or steroid therapy is being tapered<sup>(71,72)</sup>. A common cause of inpatient hypoglycemia is insulin prescription errors including misreading poorly written prescriptions – when ‘U’ is used for units (i.e. 4U becoming 40 units) or confusing the insulin name with the dose (e.g. Humalog Mix25 becoming Humalog 25 units).

Table 3 describes the most common risk factors for developing hypoglycemia in hospital<sup>73</sup>. However, other factors may also be involved, such as concurrent use of drugs with hypoglycemic agents e.g. warfarin, quinine, salicylates, fibrates, sulphonamides (including cotrimoxazole), monoamine oxidase inhibitors, NSAIDs, probenecid, somatostatin analogues, SSRIs. Secondary causes of inpatient hypoglycemia include loss of counter-regulatory hormone function, e.g. Addison’s disease, growth hormone deficiency, hypothyroidism, hypopituitarism.

**Table 3 Common risk factors for developing hypoglycemia in the hospital.**

Prior episode of hypoglycemia
Older age
Chronic kidney disease
Congestive heart failure
Malnutrition
Erratic eating patterns/Nutritional interruptions
Malignancies
Insulin regimen
Type 1 diabetes
Mental status changes
Certain concomitants use of medications
Duration of diabetes

The development of hypoglycemia is associated with poor hospital outcome<sup>(53,58,74-80)</sup>. Turchin et al examined data from 4368 admission episodes for people with diabetes of which one third were on regular insulin therapy<sup>(81)</sup>.

Patients experiencing inpatient hypoglycemia experienced a 66% increased risk of death within one year and spent 2.8 days longer in hospital compared to those not experiencing hypoglycemia. The odds ratio (95% confidence interval) for mortality associated with one or more episodes was 2.28 (1.41-3.70, p=0.0008) among a cohort of 5,365 patients admitted to a mixed medical-surgical ICU<sup>(69)</sup>. In a larger cohort of over 60,000 patients, hypoglycemia was associated with longer ICU stay and greater hospital mortality especially for patients with more than one episode of hypoglycemia.

Hypoglycemia has been associated with adverse cardiovascular outcomes, such as prolonged QT interval, ischemic electrocardiogram changes, angina, arrhythmias, sudden death, and increased inflammation<sup>(82,83)</sup>. The mechanisms for the poor outcome are not completely understood, but hypoglycemia has been associated with increases in proinflammatory cytokines (TNF $\alpha$ , IL-1 $\beta$ , IL-6, and IL-8), markers of lipid peroxidation, and oxidative stress<sup>(84,85)</sup>. In addition, acute hypoglycemia creates a prothrombotic environment, with increased levels of vasoconstrictors, endothelial dysfunction and vasoconstriction<sup>(84,86)</sup>.

Despite these observations, the direct causal effect of iatrogenic hypoglycemia on outcomes is still debatable. Kosiborod et al<sup>(77)</sup> reported that spontaneous hypoglycemia, but not insulin-induced hypoglycemia was associated with higher in-hospital mortality. Similarly, a recent study among 31,970 patients also reported that hypoglycemia is associated with increased in-hospital mortality, but the risk was limited to patients with spontaneous hypoglycemia and not to patients with drug-associated hypoglycemia<sup>(87)</sup>. These studies raised the possibility that hypoglycemia, similar to hyperglycemia, is a marker of disease burden rather than a direct cause of death.

## RECOMMENDATIONS FOR MANAGING *HYPERGLYCEMIA* IN THE HOSPITAL ENVIRONMENT

### *Management of inpatient hyperglycemia in the ICU*

Insulin is the best way to control hyperglycemia in the inpatient setting specially in the critically ill patient. Intravenously administered insulin is the preferred method to achieve the recommended glycemic target. The short half-life of intravenous insulin makes it ideal in this setting because of flexibility in the event of unpredicted changes in patient's health, medications and nutrition. When a patient is identified as having hyperglycemia (blood glucose equal or more than 10 mmol/l (180 mg/dl) intravenous insulin infusion should be started to maintain blood glucose levels below 10 mmol/l (180 mg/dl). A variety of intravenous infusion protocols have been shown to be effective in achieving glycemic control with a low rate of hypoglycemic events, and in improving hospital outcomes<sup>(20,36,39,88-91)</sup>. A proper protocol should allow flexible blood glucose targets, modified based on the patient's clinical situation. Further, it should have clear instructions about the blood glucose threshold for initiating insulin infusion and the initial rate. It should be validated in order to avoid hyperglycemia if adjusted too slowly and hypoglycemia if adjusted too fast. Accurate insulin administration requires a reliable infusion pump that can deliver the insulin dose in increments of 0.1 unit per hr<sup>(92)</sup>.

There is no ideal protocol for the management of hyperglycemia in the critical patient. In addition, there is no clear evidence demonstrating the benefit of one protocol/algorithm versus the other. The protocol should be based on the institution- ICU resources such as trained nursing personnel. The implementation of any of these algorithms requires close follow up by the nursing staff and is prone to human errors. Some institutions have developed computerized protocols that can be implemented in order to avoid errors in dosing. Essential elements that increase protocol success in continuous insulin infusion are: 1) rate adjustment considers the current and previous glucose value and the current rate of insulin infusion, 2) rate adjustment considers the rate of change (or lack of change) from the previous reading, and 3) frequent glucose monitoring (hourly until stable glycemia is established, and then every 2-3 hours)<sup>(64,91,93)</sup>.

Several computer-based algorithms aiming to direct the nursing staff adjusting the insulin infusion rate have become commercially available<sup>(94,95)</sup>. Controlled trials have reported more rapid and tighter glycemic control with computer-guided algorithms than standard paper form protocols in ICU patients<sup>(96)</sup>, as well as lower glycemic variability than patients treated with the standard insulin infusion regimens. Despite differences in glycemic control between insulin algorithms, a recent study showed no difference between computerized protocols versus conventional glucose control<sup>97</sup>. Thus, most insulin algorithms appear to be appropriate alternatives for the management of hyperglycemia in critically ill patients, and the choice depends upon physician's preferences and cost considerations<sup>(91,98,99)</sup>.

### *Managing Hyperglycemia in the non- ICU setting*

Subcutaneous insulin is the preferred therapeutic agent for glucose control in general medicine and surgery patients

admitted to non-ICU areas. Several studies have shown that the commonly used subcutaneous sliding scale insulin (SSI) is not acceptable as the single regimen in patients with diabetes, as it results in undesirable levels of hypoglycemia and hyperglycemia (<sup>100,101</sup>). It has become evident in recent years that the use of scheduled subcutaneous insulin therapy with basal (glargine or detemir) once daily or with intermediate acting insulin (NPH) given twice daily alone or in combination with short (regular) or rapid acting insulin (lispro, aspart, glulisine) prior to meals is effective and safe for the management of most patients with hyperglycemia and diabetes (<sup>102,103</sup>).

The basal bolus (prandial) insulin regimen is considered the physiologic approach as it addresses the three components of insulin requirement: basal (what is required in the fasting state), nutritional (what is required for peripheral glucose disposal following a meal), and supplemental (what is required for unexpected glucose elevations, or to dispose of glucose in hyperglycemia)(<sup>103</sup>).

A prospective, randomized multi-center trial compared the efficacy and safety of a basal/bolus insulin regimen with basal bolus regimen and SSI in patients with type 2 diabetes admitted to a general medicine service (<sup>65</sup>). The use of basal-bolus insulin had greater improvement in blood glucose control than sliding scale alone. A blood glucose target 7.8 mmol/l (< 140 mg/dl) was achieved in 66% of patients in the glargine plus glulisine group and 38% in the sliding scale group. The incidence of hypoglycemia, defined as a BG <3.3 mmol/l (<60 mg/dl), was less than 5% in patients treated with basal bolus or SSI. A different study in general surgery patients also compared efficacy and safety of a basal bolus regimen to SSI in patients with type 2 diabetes (<sup>66</sup>). The basal bolus regimen resulted in significant improvement in glucose control and in a reduction in the frequency of the composite of postoperative complications including wound infection, pneumonia, respiratory failure, acute renal failure and bacteremia.

The use of multi-dose human NPH and regular insulin has been compared to basal bolus treatment with insulin analogs in an open-label, controlled, multicenter trial in 130 medical patients with type 2 diabetes (<sup>104</sup>). This study found that both treatment regimens resulted in significant improvements in inpatient glycemic control with a glucose target of less than 140 mg/dl before meals, as well as no difference in the rate of hypoglycemic events. Thus, it appears that similar improvement in glycemic control can be achieved with either basal bolus therapy with insulin analogs or with NPH/regular human insulin in patients with type 2 diabetes.

Most patients in the hospital have reduced caloric intake due to lack of appetite, medical procedures or surgical intervention. In such patients, the recent Basal Plus trial (<sup>105</sup>) randomized patients with type 2 diabetes who were treated with diet, oral antidiabetic agents, or low-dose insulin ( $\leq 0.4$  unit/kg/day) prior to admission to receive a standard basal bolus regimen with glargine once daily and glulisine before meals and a single daily dose of glargine and supplemental doses of glulisine for correction of hyperglycemia (>140 mg/dl) per sliding scale (Basal Plus trial). This study reported that the basal approach resulted in similar improvement in glycemic control and in the frequency of hypoglycemia compared to a standard basal bolus regimen. Thus, in insulin naive patients or in those receiving low-dose insulin on admission (less than 0.4 units/kg/day), as well as patients with reduced oral intake, the use of a basal plus regimen is an effective alternative to basal bolus.

The recommended total daily insulin dose for most patients should start between 0.3 to 0.5 units per Kg (<sup>65,72,106,107</sup>). Starting doses greater than 0.6-0.8 unit/kg/day have been associated with a 3-fold higher odds of hypoglycemia than doses lower than 0.2 U/kg/day. In elderly patients in subjects with impaired renal function, lower initial daily doses ( $\leq 0.3$  units/kg) may lower the risk of hypoglycemia (<sup>24,108</sup>).

## GLUCOSE MONITORING IN HOSPITAL

All patients admitted to the hospital with a diagnosis of diabetes and those with newly discovered hyperglycemia should be monitored closely. The frequency of monitoring and the schedule of the blood glucose checks will be dependent on the nutritional intake, patient treatment and schedule of insulin. There is some controversy regarding the best method to monitor blood glucose. However, considering the convenience and wide availability of the capillary point of care (POC) testing we suggest this as the best approach as long as it is done with a monitoring device that has

demonstrated accuracy. When using POC blood glucose levels keep in mind clinical conditions that might affect the POC value such as hemoglobin level, perfusion, and medications. Below, we present Table 4 summarizing potential schedules for blood glucose monitoring based on patient nutritional intake and medical regimen.

**Table 4 Glucose monitoring schedule based on nutritional intake, insulin regimen and special patient situation.**

<b>Diet</b>	<b>Regimen</b>	<b>Glucose monitoring schedule</b>	<b>Special caveats.</b>
NPO	Intravenous insulin infusion	Every 1-2 Hrs.	
NPO	SC regular insulin every 6 hrs (6 am, noon, 6pm, midnight)	Every 6 hrs (6 am, noon, 6pm, midnight) prior to SC insulin dose	
NPO	Basal insulin alone(Glargine or Levemir)	Every 6 hr (6 am, noon, 6pm, midnight)	
Eating 3 meals per day	Basal/bolus regimen with long acting (Glargine, Levemir) and rapid-acting insulin with meals (aspart, lispro, glulisine)	4 times per day: before breakfast, before lunch, before dinner, and bedtime.	Consider a 3 am blood glucose check in patients at risk for hypoglycemia
Nocturnal tube feeds and daytime oral intake	Regimen varies depending on clinical status. Basal insulin plus corrections or basal bolus with long and rapid-acting insulin. Basal in AM and low-dose NPH insulin at the start of the nocturnal tube feeds.	5 times per day: before breakfast, before lunch, before dinner, bedtime and 3 am.	
Continued tube feeds	Basal insulin plus correction with regular insulin every 4-6 hours. NPH 2 or 3 times daily or regular insulin every 6 hrs.	Every 6 hrs (6 am, noon, 6pm, midnight)	
Patients eating small multiple meals per day. (e.g. cystic fibrosis)	Basal/bolus with long acting insulin and rapid-acting insulin with meals. (carbohydrate counting)	At least 4 times per day: before breakfast, before lunch, before dinner, and bedtime	More frequent checks might be warranted in order to include post-prandial blood glucose.
Patient on high-dose corticosteroids	Basal/bolus with long acting insulin and rapid-acting insulin with meals. May add small dose of NPH to basal bolus regimen in patients on morning dose of steroids.	4 times per day: before breakfast, before lunch, before dinner, and bedtime	
NPO or eating 3 meals per day	Patients on insulin pumps	4 -8 times per day: before breakfast, lunch, dinner, and bedtime. Consider postprandial checks.	

## **MEDICAL NUTRITION THERAPY (MNT) IN HOSPITALIZED PATIENTS WITH DIABETES.**

Medical nutrition therapy is a key component of the comprehensive management of diabetes and hyperglycemia in the

inpatient setting. Maintaining adequate nutrition is important for glycemic control and to meet adequate caloric demands. Caloric demand in acute illness will differ from that in the outpatient setting. Achieving the proper nutritional balance in the inpatient setting is challenging. All patients admitted to the hospital with diabetes or hyperglycemia should be assessed to determine the need for a modified diet in order to achieve caloric demands.

The general approach to address MNT in the inpatient setting is usually based on expert opinions and patient need. There is limited data regarding what is the best approach or method to achieve the ideal caloric supply. To determine the best approach, method, and caloric need of their patients, providers should work closely with the nutrition professional.

All patients with diabetes or hyperglycemia should receive an individualized assessment. In general, most patient will receive adequate caloric needs with 3 discrete meals per day. Further, the metabolic need for patients with diabetes is usually provided by 25 to 35 calories/kg where some critically ill patients might require less 15 to 25 calories/kg per day<sup>(109)</sup>. A consistent carbohydrate meal-planning system might help to facilitate glycemic control and insulin dosing in the inpatient setting. Most patients will require at 1,500-2000 calories per day with 12-15 grams of carbohydrates per meal<sup>(12)</sup>. Ideally, the carbohydrates should come from low glycemic index foods such as whole grains and vegetables.

Patients not able to achieve these goals should be evaluated in order to determine the need for enteral or parenteral nutrition. Enteral nutrition is the second best option after oral nutrition and should be preferred over parenteral nutrition in hospitalized patients<sup>(110,111)</sup>. There are several advantages of enteral feeding versus parenteral feeding including: low cost, low risk of complications, physiologic route and less risk for gastric mucosa atrophy and lower risk of infectious and thrombotic complications compared with the latter form of therapy<sup>(112,113)</sup>. The benefit of parental nutrition has been documented in the critically ill patient. However, some research has shown a detrimental effect on patients with diabetes and hyperglycemia. Parental nutrition should be considered only in patients that are not able to receive enteral nutrition and should be coordinated with the institution parenteral nutrition team.

Enteral and parenteral nutrition can prevent the effects of starvation and malnutrition<sup>(110,111)</sup>. The preference for use of enteral over parenteral nutrition whenever possible is due to a lower risk of infectious and thrombotic complications<sup>(112,113)</sup>. Standard enteral formulas reflect the reference values for macro- and micronutrients for a healthy population and contain 1-2 cal/ml. Most standard formulas contain whole protein, lipid in the form of long-chain triglycerides, and carbohydrates. Standard diabetes-specific formulas provide low amounts of lipids (30% of total calories) combined with a high carbohydrates (HCH) content (55–60% of total calories); however, newer diabetic formulas have replaced part of carbohydrates with monounsaturated fatty acids (up to 35% of total calories) and also include 10-15 g/l dietary fiber and up to 30% fructose<sup>(114,115)</sup>.

Diabetic enteral formulas containing low-carbohydrate high–monounsaturated fatty acid (LCHM) are preferable to standard high-carbohydrate formulas in hospitalized patients with type 1 and type 2 diabetes.<sup>(114,116)</sup> In a meta-analysis of studies comparing newer enteral LCHM formulas with standard formulations, the postprandial rise in blood glucose was reduced by 18-29 mg/dl with the newer formulations<sup>(116)</sup>. Table 5 depicts the composition of standard and diabetic specific enteral formulas commonly used in hospitalized patients.

**Table 5 Composition of standard and diabetic specific enteral formulas commonly used in hospitalized patients.**

	Calories (kcal/mL)	Carbohydrate (g/L)	Fat (g/L)	Protein (g/L)	Manufacture
<b>Standard formula</b>					
Jevity® 1.0 Cal	1.0	155	35	44	Abbott Nutrition
Nutren® 1.0	1.0	127	38	40	Nestle Nutrition

Osmolite® 1.2 Cal	1.2	158	39	55	Abbott Nutrition
Jevity® 1.2	1.2	169	39	56	Nestle Nutrition
Fibersource® HN	1.2	160	39	53	Nestle Nutrition
Isosource® 1.5 Cal	1.5	170	65	68	Nestle Nutrition
Jevity® 1.5	1.5	216	50	64	Nestle Nutrition
<b>Diabetes specific formula</b>					
Glucerna ® 1.0 Cal	1.0	96	54	42	Abbott Nutrition
Nutren® Glytrol®	1.0	100	48	45	Nestle Nutrition
Glucerna ® 1.2 Cal	1.2	115	60	60	Abbott Nutrition
Diabetisource® AC	1.2	100	59	60	Nestle Nutrition
Glucerna ® 1.5 Cal	1.5	133	75	82	Abbott Nutrition

## CORTICOSTEROID THERAPY – IMPACT ON BLOOD GLUCOSE

Steroids may be administered by various regimens and at variable doses. A single daily dose of steroid (e.g. prednisolone/prednisone) in the morning may be the commonest mode of administration. In susceptible patients, this will often result in a rise in blood glucose by late morning that continues through to the evening. Overnight the blood glucose generally often falls back to baseline levels by the next morning. Thus treatment should be tailored to treating the hyperglycemia, whilst avoiding nocturnal and early morning hypoglycemia. Multiple daily doses of steroid, be it intravenous hydrocortisone or oral dexamethasone, can cause a hyperglycemic effect throughout the 24-hour period. It may be, however, that a twice daily premixed or basal bolus regimen may need to be started if oral medication, or once daily insulin proves insufficient to control hyperglycemia. Close attention will therefore need to be paid to blood glucose monitoring and early intervention may be necessary.

Levels in most individuals can be predicted to rise approximately 4 to 8 hours following the administration of oral steroids, and sooner following the administration of intravenous steroids. Again, capillary blood glucose monitoring is paramount to guide appropriate therapeutic interventions. Conversely, glucose levels may improve to pre-steroid levels 24 hours after intravenous steroids are discontinued. If oral steroids are weaned down over several weeks, the glucose levels may decline in a dose dependent fashion, but this may not occur, particularly in those with pre-existing undiagnosed diabetes.

At the commencement of steroid therapy, or for those already on a supraphysiological dose of corticosteroid, capillary blood glucose testing should occur before meals and at bedtime, in particular before lunch or evening meal, when the hyperglycemic effects of a morning dose of steroid is likely to be greatest.

It is likely that subcutaneous insulin using a basal, or multiple daily injection regimen will be the most appropriate choice to achieve glycemic control in the event of hyperglycemia for the majority of patients. Morning administration of basal human insulin may closely fit the glucose excursion induced by a single morning dose of oral steroid. Basal analogue insulin may be appropriate if hyperglycemia is present for more prolonged periods. However, care should be taken to identify and protect against hypoglycemia overnight and in the early morning if long acting insulin analogues are used in this context. Subsequent titration of the insulin dose may be required to allow maintenance of glucose control in the face of increasing or decreasing steroid dose.

When a patient is discharged from the hospital on steroid therapy, a clear strategy for the management of hyperglycemia or potential hyperglycemia, and the titration of therapy to address the hyperglycemia, should be communicated to the community diabetes team and primary care team. Patients commenced on steroids as an inpatient and discharged after a short stay with the intention of continuing high dose steroids, should receive standard education

in regard to diabetes, encompassing the risks associated with hyperglycemia and hypoglycemia.

## REFERENCES

1. Danaei G, Finucane MM, Lu Y, et al. National, regional, and global trends in fasting plasma glucose and diabetes prevalence since 1980: systematic analysis of health examination surveys and epidemiological studies with 370 country-years and 2.7 million participants. *Lancet*. Jul 2 2011;378(9785):31-40.
2. Centers for Disease Control and Prevention. National Diabetes Statistics Report. 2014; <http://www.cdc.gov/diabetes/pubs/statsreport14/national-diabetes-report-web.pdf>. Accessed September 14, 2014.
3. Boyle JP, Thompson TJ, Gregg EW, Barker LE, Williamson DF. Projection of the year 2050 burden of diabetes in the US adult population: dynamic modeling of incidence, mortality, and prediabetes prevalence. *Population health metrics*. 2010;8:29.
4. Jiang HJ, Stryer D, Friedman B, Andrews R. Multiple hospitalizations for patients with diabetes. *Diabetes Care*. May 2003;26(5):1421-1426.
5. Donnan PT, Leese GP, Morris AD. Hospitalizations for people with type 1 and type 2 diabetes compared with the nondiabetic population of Tayside, Scotland: a retrospective cohort study of resource use. *Diabetes Care*. Dec 2000;23(12):1774-1779.
6. Umpierrez GE, Isaacs SD, Bazargan N, You X, Thaler LM, Kitabchi AE. Hyperglycemia: an independent marker of in-hospital mortality in patients with undiagnosed diabetes. *J Clin Endocrinol Metab*. Mar 2002;87(3):978-982.
7. American Diabetes A. Economic costs of diabetes in the U.S. in 2012. *Diabetes Care*. Apr 2013;36(4):1033-1046.
8. Qaseem A, Humphrey LL, Chou R, Snow V, Shekelle P. Use of intensive insulin therapy for the management of glycemic control in hospitalized patients: a clinical practice guideline from the American College of Physicians. *Annals of internal medicine*. Feb 15 2011;154(4):260-267.
9. Moghissi ES, Korytkowski MT, DiNardo M, et al. American Association of Clinical Endocrinologists and American Diabetes Association consensus statement on inpatient glycemic control. *Diabetes Care*. Jun 2009;32(6):1119-1131.
10. Cook CB, Kongable GL, Potter DJ, Abad VJ, Leija DE, Anderson M. Inpatient glucose control: a glycemic survey of 126 U.S. hospitals. *J Hosp Med*. Nov 2009;4(9):E7-E14.
11. Kosiborod M, Inzucchi SE, Spertus JA, et al. Elevated admission glucose and mortality in elderly patients hospitalized with heart failure. *Circulation*. Apr 14 2009;119(14):1899-1907.
12. Umpierrez GE, Hellman R, Korytkowski MT, et al. Management of hyperglycemia in hospitalized patients in non-critical care setting: an endocrine society clinical practice guideline. *J Clin Endocrinol Metab*. Jan 2012;97(1):16-38.
13. Corssmit EP, Romijn JA, Sauerwein HP. Review article: Regulation of glucose production with special attention to nonclassical regulatory mechanisms: a review. *Metabolism*. Jul 2001;50(7):742-755.
14. Cryer PE. Hypoglycemia, functional brain failure, and brain death. *J Clin Invest*. Apr 2007;117(4):868-870.
15. Boden G. Gluconeogenesis and glycogenolysis in health and diabetes. *J Investig Med*. Sep 2004;52(6):375-378.
16. McDonnell ME, Umpierrez GE. Insulin therapy for the management of hyperglycemia in hospitalized patients. *Endocrinology and metabolism clinics of North America*. Mar 2012;41(1):175-201.
17. Kitabchi AE, Umpierrez GE, Murphy MB, et al. Management of hyperglycemic crises in patients with diabetes. *Diabetes Care*. Jan 2001;24(1):131-153.

18. van de Werve G, Jeanrenaud B. Liver glycogen metabolism: an overview. *Diabetes/metabolism reviews*. Jan 1987;3(1):47-78.
19. Schmeltz LR, DeSantis AJ, Thiagarajan V, et al. Reduction of surgical mortality and morbidity in diabetic patients undergoing cardiac surgery with a combined intravenous and subcutaneous insulin glucose management strategy. *Diabetes Care*. Apr 2007;30(4):823-828.
20. van den Berghe G, Wouters P, Weekers F, et al. Intensive insulin therapy in the critically ill patients. *N Engl J Med*. Nov 8 2001;345(19):1359-1367.
21. Swanson CM, Potter DJ, Kongable GL, Cook CB. An Update on Inpatient Glycemic Control in U.S. Hospitals. *Endocr Pract*. May 6 2011:1-22.
22. Greci LS, Kailasam M, Malkani S, et al. Utility of HbA(1c) levels for diabetes case finding in hospitalized patients with hyperglycemia. *Diabetes Care*. Apr 2003;26(4):1064-1068.
23. Mazurek JA, Hailpern SM, Goring T, Nordin C. Prevalence of Hemoglobin A1c Greater Than 6.5% and 7.0% among Hospitalized Patients without Known Diagnosis of Diabetes at an Urban Inner City Hospital. *J Clin Endocrinol Metab*. Jan 15 2010;95(3):1344-1348.
24. Baldwin D, Villanueva G, McNutt R, Bhatnagar S. Eliminating Inpatient Sliding-Scale Insulin: A reeducation project with medical house staff. *Diabetes Care*. May 1, 2005 2005;28(5):1008-1011.
25. Gerich JE, Lorenzi M, Bier DM, et al. Effects of physiologic levels of glucagon and growth hormone on human carbohydrate and lipid metabolism. Studies involving administration of exogenous hormone during suppression of endogenous hormone secretion with somatostatin. *J Clin Invest*. Apr 1976;57(4):875-884.
26. Rizza RA, Mandarino LJ, Gerich JE. Dose-response characteristics for effects of insulin on production and utilization of glucose in man. *Am J Physiol*. Jun 1981;240(6):E630-639.
27. Scherpereel PA, Tavernier B. Perioperative care of diabetic patients. *Eur J Anaesthesiol*. May 2001;18(5):277-294.
28. Stentz FB, Umpierrez GE, Cuervo R, Kitabchi AE. Proinflammatory cytokines, markers of cardiovascular risks, oxidative stress, and lipid peroxidation in patients with hyperglycemic crises. *Diabetes*. Aug 2004;53(8):2079-2086.
29. Chaudhuri A, Umpierrez GE. Oxidative stress and inflammation in hyperglycemic crises and resolution with insulin: implications for the acute and chronic complications of hyperglycemia. *Journal of diabetes and its complications*. Jul-Aug 2012;26(4):257-258.
30. Esposito K, Nappo F, Marfella R, et al. Inflammatory cytokine concentrations are acutely increased by hyperglycemia in humans: role of oxidative stress. *Circulation*. Oct 15 2002;106(16):2067-2072.
31. Umpierrez GE, A.E. K. ICU Care for Patients with Diabetes. *Current Opinions Endocrinol*. 2004;11:75-81.
32. Lang CH, Dobrescu C, Bagby GJ. Tumor necrosis factor impairs insulin action on peripheral glucose disposal and hepatic glucose output. *Endocrinology*. Jan 1992;130(1):43-52.
33. Fan J, Li YH, Wojnar MM, Lang CH. Endotoxin-induced alterations in insulin-stimulated phosphorylation of insulin receptor, IRS-1, and MAP kinase in skeletal muscle. *Shock*. Sep 1996;6(3):164-170.
34. del Aguila LF, Claffey KP, Kirwan JP. TNF-alpha impairs insulin signaling and insulin stimulation of glucose uptake in C2C12 muscle cells. *Am J Physiol*. May 1999;276(5 Pt 1):E849-855.
35. Falciglia M, Freyberg RW, Almenoff PL, D'Alessio DA, Render ML. Hyperglycemia-related mortality in critically ill patients varies with admission diagnosis. *Crit Care Med*. Dec 2009;37(12):3001-3009.
36. Furnary AP, Gao G, Grunkemeier GL, et al. Continuous insulin infusion reduces mortality in patients with diabetes

- undergoing coronary artery bypass grafting. *J Thorac Cardiovasc Surg.* May 2003;125(5):1007-1021.
37. Umpierrez GE, Smiley D, Jacobs S, et al. Randomized study of basal-bolus insulin therapy in the inpatient management of patients with type 2 diabetes undergoing general surgery (RABBIT 2 surgery). *Diabetes Care.* Feb 2011;34(2):256-261.
38. Krinsley JS. Association between hyperglycemia and increased hospital mortality in a heterogeneous population of critically ill patients. *Mayo Clin Proc.* Dec 2003;78(12):1471-1478.
39. Furnary AP, Zerr KJ, Grunkemeier GL, Starr A. Continuous intravenous insulin infusion reduces the incidence of deep sternal wound infection in diabetic patients after cardiac surgical procedures. *Ann Thorac Surg.* Feb 1999;67(2):352-360; discussion 360-352.
40. Kotagal M, Symons RG, Hirsch IB, et al. Perioperative Hyperglycemia and Risk of Adverse Events Among Patients With and Without Diabetes. *Annals of surgery.* Apr 17 2014.
41. Rains JL, Jain SK. Oxidative stress, insulin signaling, and diabetes. *Free Radic Biol Med.* Mar 1 2011;50(5):567-575.
42. Montori VM, Bistrian BR, McMahon MM. Hyperglycemia in acutely ill patients. *Jama.* Nov 6 2002;288(17):2167-2169.
43. McAlister FA, Majumdar SR, Blitz S, Rowe BH, Romney J, Marrie TJ. The relation between hyperglycemia and outcomes in 2,471 patients admitted to the hospital with community-acquired pneumonia. *Diabetes Care.* Apr 2005;28(4):810-815.
44. Baker EH, Janaway CH, Philips BJ, et al. Hyperglycaemia is associated with poor outcomes in patients admitted to hospital with acute exacerbations of chronic obstructive pulmonary disease. *Thorax.* Apr 2006;61(4):284-289.
45. Noordzij PG, Boersma E, Schreiner F, et al. Increased preoperative glucose levels are associated with perioperative mortality in patients undergoing noncardiac, nonvascular surgery. *Eur J Endocrinol.* Jan 2007;156(1):137-142.
46. Pomposelli JJ, Baxter JK, 3rd, Babineau TJ, et al. Early postoperative glucose control predicts nosocomial infection rate in diabetic patients. *JPEN J Parenter Enteral Nutr.* Mar-Apr 1998;22(2):77-81.
47. Ramos M, Khalpey Z, Lipsitz S, et al. Relationship of perioperative hyperglycemia and postoperative infections in patients who undergo general and vascular surgery. *Annals of surgery.* Oct 2008;248(4):585-591.
48. Jacobi J, Bircher N, Krinsley J, et al. Guidelines for the use of an insulin infusion for the management of hyperglycemia in critically ill patients. *Crit Care Med.* Dec 2012;40(12):3251-3276.
49. Wernerman J, Desai T, Finfer S, et al. Continuous glucose control in the ICU: report of a 2013 round table meeting. *Crit Care.* 2014;18(3):226.
50. Amrein K, Ellmerer M, Hovorka R, et al. Efficacy and safety of glucose control with Space GlucoseControl in the medical intensive care unit--an open clinical investigation. *Diabetes Technol Ther.* Aug 2012;14(8):690-695.
51. Moghissi ES, Korytkowski MT, DiNardo M, et al. American Association of Clinical Endocrinologists and American Diabetes Association consensus statement on inpatient glycemic control. *Endocr Pract.* May-Jun 2009;15(4):353-369.
52. Dhatariya K, Levy N, Kilvert A, et al. NHS Diabetes guideline for the perioperative management of the adult patient with diabetes. *Diabet Med.* Apr 2012;29(4):420-433.
53. Van den Berghe G, Wilmer A, Hermans G, et al. Intensive insulin therapy in the medical ICU. *N Engl J Med.* Feb 2 2006;354(5):449-461.

54. Brunkhorst FM, Engel C, Bloos F, et al. Intensive insulin therapy and pentastarch resuscitation in severe sepsis. *N Engl J Med*. Jan 10 2008;358(2):125-139.
55. De La Rosa Gdel C, Donado JH, Restrepo AH, et al. Strict glycaemic control in patients hospitalised in a mixed medical and surgical intensive care unit: a randomised clinical trial. *Crit Care*. 2008;12(5):R120.
56. Finfer S, Chittock DR, Su SY, et al. Intensive versus conventional glucose control in critically ill patients. *N Engl J Med*. Mar 26 2009;360(13):1283-1297.
57. Preiser JC, Brunkhorst F. Tight glucose control and hypoglycemia. *Crit Care Med*. Apr 2008;36(4):1391; author reply 1391-1392.
58. Griesdale DE, de Souza RJ, van Dam RM, et al. Intensive insulin therapy and mortality among critically ill patients: a meta-analysis including NICE-SUGAR study data. *CMAJ*. Apr 14 2009;180(8):821-827.
59. Preiser JC, Devos P, Ruiz-Santana S, et al. A prospective randomised multi-centre controlled trial on tight glucose control by intensive insulin therapy in adult intensive care units: the Glucontrol study. *Intensive Care Med*. Oct 2009;35(10):1738-1748.
60. Finfer S, Liu B, Chittock DR, et al. Hypoglycemia and risk of death in critically ill patients. *N Engl J Med*. Sep 20 2012;367(12):1108-1118.
61. Umpierrez GE, Simley D, Jacobs S, et al. **R**andomized Study of **B**asal **B**olus Insulin Therapy in the **I**npatient Management of Patients with **T**ype **2** Diabetes Undergoing General **S**urgery (**R**ABBIT Surgery). *Diabetes Care*. February 2011;34(2):256-261.
62. Association AD. Standards of medical care in diabetes. *Diabetes Care*. Jan 2010;33 Suppl 1:S11-61.
63. Cryer PE, Axelrod L, Grossman AB, et al. Evaluation and management of adult hypoglycemic disorders: an Endocrine Society Clinical Practice Guideline. *J Clin Endocrinol Metab*. Mar 2009;94(3):709-728.
64. Krikorian A, Ismail-Beigi F, Moghissi ES. Comparisons of different insulin infusion protocols: a review of recent literature. *Curr Opin Clin Nutr Metab Care*. Mar;13(2):198-204.
65. Umpierrez GE, Smiley D, Zisman A, et al. Randomized study of basal-bolus insulin therapy in the inpatient management of patients with type 2 diabetes (RABBIT 2 trial). *Diabetes Care*. Sep 2007;30(9):2181-2186.
66. Umpierrez E, Smiley D, Jacobs S, et al. RAnDomiZed Study of Basal Bolus Insulin Therapy in the Inpatient Management of Patients with Type 2 Diabetes Undergoing General Surgery (RABBIT 2 Surgery). *Diabetes*. 2010;59(suppl 1).
67. Rajendran R, Kerry C, Rayman G, Ma GICsg. Temporal patterns of hypoglycaemia and burden of sulfonylurea-related hypoglycaemia in UK hospitals: a retrospective multicentre audit of hospitalised patients with diabetes. *BMJ Open*. 2014;4(7):e005165.
68. Rajendran R, Rayman G. Serious harm from inpatient hypoglycaemia: a survey of hospitals in the UK. *Diabet Med*. Oct 2014;31(10):1218-1221.
69. Krinsley JS, Grover A. Severe hypoglycemia in critically ill patients: risk factors and outcomes. *Crit Care Med*. Oct 2007;35(10):2262-2267.
70. Kagansky N, Levy S, Rimon E, et al. Hypoglycemia as a predictor of mortality in hospitalized elderly patients. *Arch Intern Med*. Aug 11-25 2003;163(15):1825-1829.
71. Smith WD, Winterstein AG, Johns T, Rosenberg E, Sauer BC. Causes of hyperglycemia and hypoglycemia in adult inpatients. *Am J Health Syst Pharm*. Apr 1 2005;62(7):714-719.

72. Maynard G, Lee J, Phillips G, Fink E, Renvall M. Improved inpatient use of basal insulin, reduced hypoglycemia, and improved glycemic control: effect of structured subcutaneous insulin orders and an insulin management algorithm. *J Hosp Med.* Jan 2009;4(1):3-15.
73. Dendy JA, Chockalingam V, Tirumalasetty NN, et al. Identifying Risk Factors for Severe Hypoglycemia in Hospitalized Patients with Diabetes. *Endocr Pract.* Jun 16 2014;1-16.
74. Zoungas S, Patel A, Chalmers J, et al. Severe hypoglycemia and risks of vascular events and death. *N Engl J Med.* Oct 7 2010;363(15):1410-1418.
75. Preiser JC, Devos P, Ruiz-Santana S, et al. A prospective randomised multi-centre controlled trial on tight glucose control by intensive insulin therapy in adult intensive care units: the Glucontrol study. *Intensive Care Med.* Jul 28 2009.
76. Wiener RS, Wiener DC, Larson RJ. Benefits and risks of tight glucose control in critically ill adults: a meta-analysis. *JAMA.* Aug 27 2008;300(8):933-944.
77. Kosiborod M, Inzucchi SE, Goyal A, et al. Relationship between spontaneous and iatrogenic hypoglycemia and mortality in patients hospitalized with acute myocardial infarction. *Jama.* Apr 15 2009;301(15):1556-1564.
78. Arabi YM, Tamim HM, Rishu AH. Hypoglycemia with intensive insulin therapy in critically ill patients: predisposing factors and association with mortality. *Crit Care Med.* Sep 2009;37(9):2536-2544.
79. Vriesendorp TM, DeVries JH, van Santen S, et al. Evaluation of short-term consequences of hypoglycemia in an intensive care unit. *Crit Care Med.* Nov 2006;34(11):2714-2718.
80. Krinsley JS, Schultz MJ, Spronk PE, et al. Mild hypoglycemia is independently associated with increased mortality in the critically ill. *Crit Care.* Jul 25 2011;15(4):R173.
81. Turchin A, Matheny ME, Shubina M, Scanlon JV, Greenwood B, Pendergrass ML. Hypoglycemia and clinical outcomes in patients with diabetes hospitalized in the general ward. *Diabetes Care.* Jul 2009;32(7):1153-1157.
82. Gill GV, Woodward A, Casson IF, Weston PJ. Cardiac arrhythmia and nocturnal hypoglycaemia in type 1 diabetes--the 'dead in bed' syndrome revisited. *Diabetologia.* Jan 2009;52(1):42-45.
83. Desouza C, Salazar H, Cheong B, Murgo J, Fonseca V. Association of hypoglycemia and cardiac ischemia: a study based on continuous monitoring. *Diabetes Care.* May 2003;26(5):1485-1489.
84. Desouza CV, Bolli GB, Fonseca V. Hypoglycemia, diabetes, and cardiovascular events. *Diabetes Care.* Jun 2010;33(6):1389-1394.
85. Razavi Nematollahi L, Kitabchi AE, Stentz FB, et al. Proinflammatory cytokines in response to insulin-induced hypoglycemic stress in healthy subjects. *Metabolism.* Apr 2009;58(4):443-448.
86. Rana OA, Byrne CD, Greaves K. Intensive glucose control and hypoglycaemia: a new cardiovascular risk factor? *Heart.* 2013; <http://heart.bmj.com/content/early/2013/05/21/heartjnl-2013-303871.abstract>. Accessed September 6, 2013.
87. Boucai L, Southern WN, Zonszein J. Hypoglycemia-associated Mortality Is Not Drug-associated but Linked to Comorbidities. *Am J Med.* Nov 2011;124(11):1028-1035.
88. Malmberg KA, Efendic S, Ryden LE. Feasibility of insulin-glucose infusion in diabetic patients with acute myocardial infarction. A report from the multicenter trial: DIGAMI. *Diabetes Care.* Sep 1994;17(9):1007-1014.
89. Umpierrez GE, Kelly JP, Navarrete JE, Casals MM, Kitabchi AE. Hyperglycemic crises in urban blacks. *Arch Intern Med.* Mar 24 1997;157(6):669-675.

90. Brown G, Dodek P. Intravenous insulin nomogram improves blood glucose control in the critically ill. *Crit Care Med*. Sep 2001;29(9):1714-1719.
91. Goldberg PA, Siegel MD, Sherwin RS, et al. Implementation of a safe and effective insulin infusion protocol in a medical intensive care unit. *Diabetes Care*. Feb 2004;27(2):461-467.
92. Boutin JM, Gauthier L. Insulin infusion therapy in critically ill patients. *Can J Diabetes*. Apr 2014;38(2):144-150.
93. Donihi A, Rea R, Haas L, Donahoe M, Korytkowski M. Safety and effectiveness of a standardized 80-150mg/dl iv insulin infusion protocol in the Medical Intensive care unit: >11,000 hours of experience. *Diabetes*. 2006;55(Suppl 1):459-P.
94. Davidson PC, Steed RD, Bode BW. Glucommander: a computer-directed intravenous insulin system shown to be safe, simple, and effective in 120,618 h of operation. *Diabetes Care*. Oct 2005;28(10):2418-2423.
95. Juneja R, Roudebush C, Kumar N, et al. Utilization of a computerized intravenous insulin infusion program to control blood glucose in the intensive care unit. *Diabetes Technol Ther*. Jun 2007;9(3):232-240.
96. Newton CA, Smiley D, Bode BW, et al. A comparison study of continuous insulin infusion protocols in the medical intensive care unit: computer-guided vs. standard column-based algorithms. *J Hosp Med*. Oct 2010;5(8):432-437.
97. Kalfon P, Giraudeau B, Ichai C, et al. Tight computerized versus conventional glucose control in the ICU: a randomized controlled trial. *Intensive Care Med*. Feb 2014;40(2):171-181.
98. DeSantis AJ, Schmeltz LR, Schmidt K, et al. Inpatient management of hyperglycemia: the Northwestern experience. *Endocr Pract*. Sep-Oct 2006;12(5):491-505.
99. Rea RS, Donihi AC, Bobeck M, et al. Implementing an intravenous insulin infusion protocol in the intensive care unit. *Am J Health Syst Pharm*. Feb 15 2007;64(4):385-395.
100. Umpierrez G, Maynard G. Glycemic chaos (not glycemic control) still the rule for inpatient care: how do we stop the insanity? *Journal of Hospital Medicine*. May 2006;1(3):141-144.
101. Hirsch IB. Sliding scale insulin--time to stop sliding. *Jama*. Jan 14 2009;301(2):213-214.
102. Moghissi ES, Korytkowski MT, DiNardo MM, et al. American Association of Clinical Endocrinologists and American Diabetes Association Consensus Statement on Inpatient Glycemic Control. *Diabetes Care*. 2009;32(6):1119-1131.
103. King AB, Armstrong DU. Basal bolus dosing: a clinical experience. *Current diabetes reviews*. May 2005;1(2):215-220.
104. Hor T, Smiley D, Munoz C, et al. Comparison of Inpatient Insulin Regimens: DEtemir plus Aspart vs. NPH plus regular in Medical Patients with Type 2 Diabetes (DEAN Trial). *Diabetes 57 (Suppl 1) 458A*. 2008.
105. Umpierrez GE, Smiley D, Hermayer K, et al. Randomized study comparing a Basal-bolus with a basal plus correction insulin regimen for the hospital management of medical and surgical patients with type 2 diabetes: basal plus trial. *Diabetes Care*. Aug 2013;36(8):2169-2174.
106. Clement S, Braithwaite SS, Magee MF, et al. Management of diabetes and hyperglycemia in hospitals. *Diabetes Care*. Feb 2004;27(2):553-591.
107. Pietras SM, Hanrahan P, Arnold LM, Sternthal E, McDonnell ME. State-of-the-art inpatient diabetes care: the evolution of an academic hospital. *Endocr Pract*. May-Jun 2010;16(3):512-521.
108. Rubin DJ, Rybin D, Doros G, McDonnell ME. Weight-based, insulin dose-related hypoglycemia in hospitalized

patients with diabetes. *Diabetes Care*. Aug 2011;34(8):1723-1728.

109. Gosmanov AR, Umpierrez GE. Medical nutrition therapy in hospitalized patients with diabetes. *Current diabetes reports*. Feb 2012;12(1):93-100.

110. Guidelines for the use of parenteral and enteral nutrition in adult and pediatric patients. *JPEN J Parenter Enteral Nutr*. Jan-Feb 2002;26(1 Suppl):1SA-138SA.

111. Cresci G. Targeting the use of specialized nutritional formulas in surgery and critical care. *JPEN J Parenter Enteral Nutr*. Jan-Feb 2005;29(1 Suppl):S92-95.

112. McMahon MM, Rizza RA. Nutrition support in hospitalized patients with diabetes mellitus. *Mayo Clin Proc*. Jun 1996;71(6):587-594.

113. Schafer RG, Bohannon B, Franz M, et al. Translation of the diabetes nutrition recommendations for health care institutions. *Diabetes Care*. Jan 1997;20(1):96-105.

114. Kreyman KG, Berger MM, Deutz NE, et al. ESPEN Guidelines on Enteral Nutrition: Intensive care. *Clin Nutr*. Apr 2006;25(2):210-223.

115. Via MA, Mechanick JI. Inpatient enteral and parental nutrition for patients with diabetes. *Current diabetes reports*. Apr 2010;11(2):99-105.

116. Elia M, Ceriello A, Laube H, Sinclair AJ, Engfer M, Stratton RJ. Enteral nutritional support and use of diabetes-specific formulas for patients with diabetes: a systematic review and meta-analysis. *Diabetes Care*. Sep 2005;28(9):2267-2279.

117. Lazar HL, McDonnell M, Chipkin SR, et al. The Society of Thoracic Surgeons practice guideline series: Blood glucose management during adult cardiac surgery. *Ann Thorac Surg*. Feb 2009;87(2):663-669.

118. Lazar HL, Chipkin SR, Fitzgerald CA, Bao Y, Cabral H, Apstein CS. Tight glycemic control in diabetic coronary artery bypass graft patients improves perioperative outcomes and decreases recurrent ischemic events. *Circulation*. Mar 30 2004;109(12):1497-1502.

119. Gandhi GY, Nuttall GA, Abel MD, et al. Intensive intraoperative insulin therapy versus conventional glucose management during cardiac surgery: a randomized trial. *Annals of internal medicine*. Feb 20 2007;146(4):233-243.

120. Hirsch IB. Understanding low sugar from NICE-SUGAR. *N Engl J Med*. Sep 20 2012;367(12):1150-1152.

121. Agus MS, Steil GM, Wypij D, et al. Tight glycemic control versus standard care after pediatric cardiac surgery. *N Engl J Med*. Sep 27 2012;367(13):1208-1219.

122. Macrae D, Grieve R, Allen E, et al. A randomized trial of hyperglycemic control in pediatric intensive care. *N Engl J Med*. Jan 9 2014;370(2):107-118.

123. Cinotti R, Ichai C, Orban JC, et al. Effects of tight computerized glucose control on neurological outcome in severely brain injured patients: A multicenter sub-group analysis of the randomized-controlled open-label CGAO-REA study. *Crit Care*. Sep 5 2014;18(5):498.

124. Okabayashi T, Shima Y, Sumiyoshi T, et al. Intensive versus intermediate glucose control in surgical intensive care unit patients. *Diabetes Care*. Jun 2014;37(6):1516-1524.

Copyright © 2000-2016, MDText.com, Inc.

This electronic version has been made freely available under a Creative Commons (CC-BY-NC-ND) license. A copy of the license can be viewed at <http://creativecommons.org/licenses/by-nc-nd/2.0/>.

Bookshelf ID: NBK279093 PMID: 25905318